HER2-Positive Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HER2-Positive Gastric Cancer Market Outlook

Thelansis’s “HER2-Positive Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HER2-Positive Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

HER2-Positive Gastric Cancer Overview

HER2-positive gastric cancer refers to a specific subtype of stomach cancer that is characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a gene that plays a role in normal cell growth, but when overexpressed in cancer cells, it can promote the growth and spread of cancer. In gastric cancer, HER2 overexpression is found in a subset of tumors, estimated to be around 10-20% of cases. The overexpression of HER2 is typically assessed through immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) testing on a tissue biopsy taken during diagnostic procedures. The significance of HER2 overexpression in gastric cancer is that it can be a predictive biomarker for targeted therapy. Trastuzumab (Herceptin) is a monoclonal antibody targeting the HER2 protein. It is effective in the treatment of HER2-positive gastric cancer, both in advanced and early-stage disease. Patients with HER2-positive gastric cancer may receive a combination of chemotherapy and trastuzumab. The addition of trastuzumab to chemotherapy has been associated with improved survival outcomes in HER2-positive gastric cancer patients.

• The prevalence of HER2-positive gastric cancer is 22%, with HER2 overexpression in gastric cancer varying between 6% and 30%, depending on the primary tumor's location. Higher rates of HER2 positivity are observed in tumors located at the gastroesophageal junction (GEJ) or stomach cardia than those originating more distally in the stomach.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: